Drug intelligence / Profile preview

BSP-201

Development stage
Unknown
Lead developer
BSP Pharmaceuticals
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

BSP-201 is a botanical extract derived from sheanut oil (Vitellaria paradoxa), developed by BSP Pharma A/S as an anti-inflammatory nutraceutical for the management of osteoarthritis. The extract is concentrated in triterpene esters, including butyrospermol, lupeol, and alpha and beta amyrin, which function by inhibiting the production of key pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Clinical studies have demonstrated that BSP-201 effectively reduces pain, stiffness, and physical dysfunction in patients with osteoarthritis of the knees and hips. It is commercially available under the brand name FlexNow Joint Formula and has been extensively researched under the designations SheaFlex70 and SheaFlex75. The product holds GRAS status in the United States and is regulated as a dietary ingredient.

Brand names
FlexNow Joint FormulaSheaFlex70SheaFlex-70SheaFlex 70SheaFlex75SheaFlex-75SheaFlex 75
Other names
sheanut oil extractshea butter extractVitellaria paradoxa extractButyrospermum parkii extract
02

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)

Beyond the preview

Go deeper on BSP-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSP-201.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call